Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
As of today, Gilead Sciences(GILD) shares are valued at $135.42. The company's market cap stands at 168.13B, with a P/E ratio of 18.28 and a dividend yield of 2.4%.
As of 2026-05-26, Gilead Sciences(GILD) stock has fluctuated between $134.19 and $136.32. The current price stands at $135.42, placing the stock +0.9% above today's low and -0.7% off the high.
Gilead Sciences(GILD) shares are trading with a volume of 2.65M, against a daily average of 5.59M.
During the past year, Gilead Sciences(GILD) stock moved between $104.46 at its lowest and $157.29 at its peak.
During the past year, Gilead Sciences(GILD) stock moved between $104.46 at its lowest and $157.29 at its peak.
GILD News
The United States market has experienced a notable uptick, rising 1.1% over the last week and achieving a 29% increase over the past year, with earnings project...
Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation an...
Gilead Sciences (NasdaqGS:GILD) completed its acquisition of Tubulis, adding next generation antibody drug conjugate technologies to its oncology portfolio. Th...
Analyst ratings
78%
of 32 ratingsMore GILD News
Gilead (GILD) Sciences announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recomm...
The analyst who called NVIDIA in 2010 just named his top 10 stocks and Gilead Sciences wasn't one of them. Get them here FREE . Gilead Sciences (GILD) more tha...
Gilead (GILD) Sciences announced the completion of its previously announced acquisition of Tubulis GmbH, a private Germany-based, clinical-stage biotechnology c...
Gilead (GILD) Sciences announced a renewed five-year collaboration with the World Health Organization, committing funding, strategic support and product donatio...
Start a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Samuel about stocks, your portfolio, or the market and get instant, person...
Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affe...
Maxim analyst Michael Okunewitch upgraded Gilead (GILD) to Buy from Hold with a $165 price target The company’s growth in the base business is expected to reach...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.